Curated News
By: NewsRamp Editorial Staff
September 15, 2026
Cancer Patients Fly to China for Treatment as US Costs Soar
TLDR
- American cancer patients seek faster, cheaper treatment in China, pressuring US firms like Calidi Biotherapeutics to cut immunotherapy costs and retain market share.
- Calidi Biotherapeutics develops immunotherapies while US patients travel to China for affordable cancer care, highlighting systemic healthcare cost challenges.
- Patients traveling to China for cancer treatment reveals urgent need for affordable care, inspiring efforts to make quality healthcare accessible worldwide.
- China emerges as a surprising destination for cutting-edge cancer therapy, as Americans bypass the costly US system for affordable alternatives.
Impact - Why it Matters
This news matters because it underscores the severe accessibility and affordability crisis in the U.S. healthcare system, which is driving patients to seek life-saving treatments abroad. For biotechnology companies like Calidi Biotherapeutics, this trend highlights the critical need to not only innovate but also ensure that new therapies are affordable and accessible to the patients who need them most. If left unaddressed, the U.S. risks losing its position as a leader in healthcare innovation and patient care, as more Americans look overseas for solutions.
Summary
For decades, lots of American patients have been traveling to “fringe” countries like Turkey, Cuba and Thailand in search of affordable, quality healthcare due to the persistent challenges plaguing the American health care system. Now the latest destination of choice for cancer treatment is China, according to a report by the WSJ (Wall Street Journal). This trend underscores the growing desperation of patients seeking cutting-edge therapies that are either unavailable or unaffordable in the United States.
For firms like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that are also conducting R&D programs aimed at commercializing the next wave of immunotherapies, affordability is a major concern because it may not be helpful to develop innovative treatments if patients cannot access them. The news highlights the urgent need for solutions that balance innovation with accessibility, especially as more patients look abroad for care.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]
BioMedWire is powered by IBN
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Cancer Patients Fly to China for Treatment as US Costs Soar
